# CM5480 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cm5480

> The next catalyst for CM5480, sponsored by CalciMedica, Inc. (CALC), is its topline data readout, 2H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for CM5480?

The next catalyst for CM5480, sponsored by CalciMedica, Inc. (CALC), is its topline data readout, 2H 2027. SEC Form 10-Q: "Specifically, we expect that our cash, cash equivalents and short-term investments will allow us to fund our current operating plan into the second half of 2027 through the anticipated data readout of our planned Phase 1b proof-of-concept study of Auxora in patients with PH and our planned submission of an IND for CM5480 in PH." [Calendar and source filings](https://sec-api.dev/pdufa/cm5480)

Source: SEC Form 10-Q, accession 0001193125-26-455490, https://www.sec.gov/Archives/edgar/data/1534133/000119312526455490/ck0001534133-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/pdufa/cm5480#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | CM5480 |
| Codes | CM5480 |
| Sponsor | CalciMedica, Inc. (CALC) https://sec-api.dev/companies/calc/catalysts |
| Indications | [acute kidney injury](https://sec-api.dev/indications/acute-kidney-injury) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jul 2024: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2026-08-11, last confirmed 2026-11-10.
- SEC Form 10-Q (accession 0001193125-26-455490): "We also initiated a Phase 2 trial of Auxora in AKI in July 2024, which we refer to as KOURAGE." https://www.sec.gov/Archives/edgar/data/1534133/000119312526455490/ck0001534133-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-344689): "We also initiated a Phase 2 trial of Auxora in AKI in July 2024, which we refer to as KOURAGE." https://www.sec.gov/Archives/edgar/data/1534133/000119312526344689/ck0001534133-20260630.htm

### Jan 2026: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: acute kidney injury.
- First seen 2026-03-03, last confirmed 2026-05-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-218134): "The Company initiated a Phase 2 trial (KOURAGE; NCT06374797) evaluating Auxora in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF); in January 2026, CalciMedica paused enrollment in the trial following a recommendation from the Independent Data Monitoring Committee and, as a next step, plans to discuss potential future development in AKI with the FDA." https://www.sec.gov/Archives/edgar/data/1534133/000119312526218134/ck0001534133-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-086658): "The Company initiated a Phase 2 trial (KOURAGE; NCT06374797) evaluating Auxora in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF); in January 2026, the trial was discontinued following a recommendation from the Independent Data Monitoring Committee, and the Company plans to discuss potential future development in AKI with the FDA." https://www.sec.gov/Archives/edgar/data/1534133/000119312526086658/ck0001534133-ex99_1.htm

### 2H 2027: topline data readout

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2026-11-10, last confirmed 2026-11-10.
- SEC Form 10-Q (accession 0001193125-26-455490): "Specifically, we expect that our cash, cash equivalents and short-term investments will allow us to fund our current operating plan into the second half of 2027 through the anticipated data readout of our planned Phase 1b proof-of-concept study of Auxora in patients with PH and our planned submission of an IND for CM5480 in PH." https://www.sec.gov/Archives/edgar/data/1534133/000119312526455490/ck0001534133-20260930.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cm5480.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CM5480 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cm5480

```bibtex
@misc{secapidev_pdufa_cm5480_20261116,
  title        = {CM5480 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cm5480}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cm5480_20261116","title":"CM5480 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cm5480","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
